Journal
NANOMEDICINE
Volume 6, Issue 10, Pages 1771-1785Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/NNM.11.162
Keywords
immune response; leukocytes; liposomes; nanomedicine; RNAi
Funding
- Levy family trust
- EU
- Israel Science Foundation [181/10]
- I-core excellence center
- Alon Foundation
- Israel CSO in the ministry of trade
Ask authors/readers for more resources
RNAi is a ubiquitous and highly specific, endogenous, evolutionarily conserved mechanism of gene silencing. RNAi holds great promise as a novel therapeutic modality. Despite the rapid progress in the understanding and utilization of RNAi in vitro, the application of RNAi in vivo has been met with great difficulties, mainly in the delivery of these molecules into specific cell types. Here, we describe the major systemic nanomedicine platforms that have been developed. Focus is given to the development of new strategies to target subsets of leukocytes, which are among the most difficult cells to transduce with RNAi. Finally, we discuss the hurdles and potential opportunities for in vivo manipulation of the immune response utilizing RNAi nanomedicines.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available